{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:27:37Z","timestamp":1790486857388,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21877056"],"award-info":[{"award-number":["21877056"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21672092"],"award-info":[{"award-number":["21672092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372667"],"award-info":[{"award-number":["82372667"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573814"],"award-info":[{"award-number":["82573814"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273059"],"award-info":[{"award-number":["82273059"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018555","name":"Science and Technology Program of Guizhou Province","doi-asserted-by":"publisher","award":["ZK-2024-Key-097"],"award-info":[{"award-number":["ZK-2024-Key-097"]}],"id":[{"id":"10.13039\/501100018555","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bioorg.2025.109186","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:20:00Z","timestamp":1762298400000},"page":"109186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Evaluation of anti-tumor activity of borated camptothecin derivatives targeting topoisomerase 1 against hepatocellular carcinoma and intrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"167","author":[{"given":"Mi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanrui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisha","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruitao","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2025.109186_bb0005","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109186_bb0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.bioorg.2025.109186_bb0015","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/13543784.2020.1792443","article-title":"Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer","volume":"29","author":"Bartsch","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109186_bb0020","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00280-018-3720-7","article-title":"Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics","volume":"83","author":"Kumler","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"29","key":"10.1016\/j.bioorg.2025.109186_bb0025","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","article-title":"Phase I\/II trial of labetuzumab Govitecan (anti-CEACAM5\/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal Cancer","volume":"35","author":"Dotan","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109186_bb0030","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of eukaryotic topoisomerases in transcription, replication and genomic stability","volume":"17","author":"Pommier","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109186_bb0035","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1021\/cr900097c","article-title":"DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition","volume":"109","author":"Pommier","year":"2009","journal-title":"Chem. Rev."},{"issue":"31","key":"10.1016\/j.bioorg.2025.109186_bb0040","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.2174\/092986712803833272","article-title":"Flavonoids acting on DNA topoisomerases: recent advances and future perspectives in cancer therapy","volume":"19","author":"Russo","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2025.109186_bb0045","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1021\/ja00968a057","article-title":"Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2","volume":"88","author":"Wall","year":"1966","journal-title":"J. Am. Chem. Soc."},{"issue":"Suppl. 6","key":"10.1016\/j.bioorg.2025.109186_bb0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1634\/theoncologist.9-90006-33","article-title":"Topotecan in the first-line treatment of small cell lung cancer","volume":"9","author":"Stewart","year":"2004","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.bioorg.2025.109186_bb0055","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1054\/bjoc.2000.1303","article-title":"Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups","volume":"83","author":"Freyer","year":"2000","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2025.109186_bb0060","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/JTO.0b013e31824b23cb","article-title":"Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients","volume":"7","author":"Kim","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109186_bb0065","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bcp.2007.10.016","article-title":"Next generation topoisomerase I inhibitors: rationale and biomarker strategies","volume":"75","author":"Teicher","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109186_bb0070","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1021\/acs.jmedchem.7b01297","article-title":"Neutral porphyrin derivative exerts anticancer activity by targeting cellular topoisomerase I (Top1) and promotes apoptotic cell death without stabilizing Top1-DNA cleavage complexes","volume":"61","author":"Das","year":"2018","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109186_bb0075","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"14","key":"10.1016\/j.bioorg.2025.109186_bb0080","doi-asserted-by":"crossref","first-page":"8231","DOI":"10.1021\/acs.chemrev.8b00561","article-title":"Metallomimetic chemistry of boron","volume":"119","author":"Legare","year":"2019","journal-title":"Chem. Rev."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109186_bb0085","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4155\/fmc.13.38","article-title":"Boron chemicals in diagnosis and therapeutics","volume":"5","author":"Das","year":"2013","journal-title":"Future Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109186_bb0090","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1016\/j.apsb.2021.01.010","article-title":"Recent developments in the medicinal chemistry of single boron atom-containing compounds","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.bioorg.2025.109186_bb0095","first-page":"401","article-title":"Ixazomib: an Oral proteasome inhibitor for the treatment of multiple myeloma","volume":"8","author":"Ramirez","year":"2017","journal-title":"J. Adv. Pract. Oncol."},{"issue":"24","key":"10.1016\/j.bioorg.2025.109186_bb0100","doi-asserted-by":"crossref","first-page":"15387","DOI":"10.1073\/pnas.242259599","article-title":"The mechanism of topoisomerase I poisoning by a camptothecin analog","volume":"99","author":"Staker","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"21","key":"10.1016\/j.bioorg.2025.109186_bb0105","doi-asserted-by":"crossref","first-page":"8388","DOI":"10.1021\/ja204075s","article-title":"Computer review of ChemDraw ultra 12.0","volume":"133","author":"Cousins","year":"2011","journal-title":"J. Am. Chem. Soc."},{"issue":"16","key":"10.1016\/j.bioorg.2025.109186_bb0110","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109186_bb0115","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.bioorg.2025.109186_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121964","article-title":"(S)-10-Hydroxycamptothecin inhibits Esophageal squamous cell carcinoma growth in vitro and in vivo via decreasing topoisomerase I enzyme activity","volume":"11","author":"Song","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.bioorg.2025.109186_bb0125","doi-asserted-by":"crossref","first-page":"8700","DOI":"10.1021\/jm101249z","article-title":"Antitumor agents 286. Design, synthesis, and structure-activity relationships of 3\u2019R,4\u2019R-disubstituted-2\u2032,2\u2032-dimethyldihydropyrano[2,3-f]chromone (DSP) analogues as potent chemosensitizers to overcome multidrug resistance","volume":"53","author":"Zhou","year":"2010","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825010661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825010661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T21:18:26Z","timestamp":1766092706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825010661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"alternative-id":["S0045206825010661"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109186","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of anti-tumor activity of borated camptothecin derivatives targeting topoisomerase 1 against hepatocellular carcinoma and intrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109186"}}